Wed.Dec 23, 2020

article thumbnail

Merck signs $356M deal to supply US with experimental coronavirus drug

Bio Pharma Dive

The drugmaker spent $425 million a month ago to acquire the biotech developer of the treatment, which tamps down on the body's inflammatory response to viral infections.

Drugs 364
article thumbnail

Is DTC effective?

World of DTC Marketing

According to a study in the Journal for American Board of Family Medicine “respondents (76%) said they were likely to ask a health care provider about advertised drugs; 26% said they had already done so. Among the 26% of respondents who talked to a health care provider about a specific prescription drug they saw advertised, 16% said they received a prescription for the advertised drug.

Doctors 249
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

US pays another $2B to buy more doses of Pfizer, BioNTech coronavirus vaccine

Bio Pharma Dive

The new deal will provide the U.S. with 100 million additional doses of Pfizer and BioNTech's shot, but the much-needed supply won't be available for several months.

article thumbnail

Botanical Solution Inc. (BSI) Secures $3.3 Million in Funding with Second Round Planned for Spring 2021

Pharma Mirror

Davis, CA: Botanical Solution Inc. (BSI), innovator of sustainable, highly consistent and cost effective Advanced Botanical Materials, has successfully secured $3.3 million in a seed round of funding, and is planning another round of funding for Spring 2021. The Spring 2021 Round of funding will boost BSI’s proven ability to discover and develop novel botanical products that are sustainable, highly consistent and cost effective.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Therapeutics for ‘COVID-19 Long-Haulers’ Exploding onto the Scene as 2020 Ends

BioSpace

BioSpace spoke with just a couple of companies endeavoring to make 2021 a happier new year for survivors now suffering from the life-altering after-effects of COVID-19.

145
145
article thumbnail

Benefits of Medical Software Company Products

Pharma Mirror

During the last couple of years, medical software has gained a lot of momentum. It’s crucial for monitoring the health of patients, and it’s one of the best ways to put human ingenuity to use. The market for this niche is getting bigger, and it’s going to cross 30 billion dollars soon. Managers and local clinics need to know about all the benefits of using these kinds of programs.

More Trending

article thumbnail

NHS leaders urge UK government to extend Brexit transition period

pharmaphorum

NHS leaders have written to the UK prime minister urging him to extend the Brexit transition period by a month to avoid plunging the healthcare service into chaos on 1 January. The letter, published today by the NHS Confederation – a membership organisation representing NHS leaders from all parts of the health service, outlines concerns about the impact a no-deal outcome will have on delivering care to patients amid winter pressures and a rapid rise in COVID-19 infections. “The failu

Medicine 128
article thumbnail

Wishing You More Affordable Medicine This Christmas

Pharmacy Checkers

With some stops and starts, this blog has become far more focused on policy, regulatory matters, law and politics — and less on everyday consumer issues relating to drug prices. With Christmas upon us, I want to extoll PharmacyChecker.com’s simple core mission: make it easier for Americans to pay for their prescription drugs. Ask PharmacyChecker , the consumer journalistic section of PharmacyChecker, has a great piece up today called The Gift of Low Drug Prices.

Medicine 119
article thumbnail

Servier beefs up in cancer, buying Agios’ oncology business for $1.8bn

pharmaphorum

French pharmaceutical company Servier has swooped on Agios Pharma’s marketed and experimental cancer drugs, buying the entire franchise in a deal that leaves the US biopharma focused on genetic disorders. It’s a major change of direction for Boston-based Agios, which has been concentrating on the oncology market since its inception in 2008, bringing the Bristol Myers Squibb-partnered Tibsovo (ivosidenib) for IDH1-mutant acute myeloid leukaemia to the US market.

article thumbnail

Molecular reporters expose the allies of the brain tumor

Scienmag

Credit: Gargiulo Lab, MDC Glioblastoma is the most common malignant brain tumor in adults. Roughly five in every 100,000 people develop this type of cancer each year. The diagnosis amounts to a death sentence: Even after surgical resection followed by radiation and chemotherapy, the glioblastoma will kill the patient in a few months. This is […].

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

COVID-19 immunity lasts eight months, say scientists: giving 'real hope' for long term vaccine protection

BioPharma Reporter

People who have been infected with SARS-CoV-2 retain immune memory to protect against reinfection for 'at least eight months', according to Australian scientists. "This research is the strongest evidence for the likelihood that vaccines against the virus will work for long periods," they say.

Scientist 105
article thumbnail

Scientists identify new gene involved in autism spectrum disorder

Scienmag

Forward genetics pinpoints gene linked to ASD involving severe speech impairment and opens door to search for more mutations, future treatments Credit: Photo taken by Brian Coats for UT Southwestern Medical Center DALLAS – Dec. 22, 2020 – UT Southwestern scientists have adapted a classic research technique called forward genetics to identify new genes involved […].

article thumbnail

Ingredients, innovation and a need for speed: what’s in store for 2021

Outsourcing Pharma

Three leaders from pharma ingredients and innovation firm Lonza share views on challenges and opportunities likely to face the industry in coming months.

article thumbnail

Research Roundup: UK Strain of COVID-19 and More

BioSpace

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Research 122
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

EU green light for Zogenix’s Fintepla

Pharma Times

Oral solution approved to treat seizures associated with Dravet syndrome

129
129
article thumbnail

Christmas trees can be green because of a photosynthetic short-cut

Scienmag

Credit: Montage by Stefan Jansson and Pushan Bag How can conifers that are used for example as Christmas trees keep their green needles over the boreal winter when most trees shed their leaves? Science has not provided a good answer to this question but now an international team of scientists, including researchers from Umeå University, […].

article thumbnail

AMO Pharma launches late-stage study of CMD candidate

Pharma Times

REACH-CDM study was based on results of positive phase II data

129
129
article thumbnail

2020 review – Pharma’s progress outside of COVID-19

pharmaphorum

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. But there was some considerable progress in other fields of medicine even though research efforts were diverted away, reports Richard Staines. The American Society of Clinical Oncology (ASCO) annual conference was one of the highlights of the year in cancer research and the fact it was held virtually did not distract from some stunni

article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

article thumbnail

Amgen files KRAS inhibitor sotorasib with EMA

Pharma Times

Submission supported by results from phase II CodeBreaK 100 study

125
125
article thumbnail

What to Know of Covid-19 Antibody Drugs: Cost, Availability and More

NY Times

Here’s information about who these therapies can help, how much they cost and how to find out if you can get them where you live.

article thumbnail

Shionogi’s novel antibiotic added to UK’s pilot subscription reimbursement model

Pharma Times

Payment for drug linked to value to NHS rather than volume used

Drugs 124
article thumbnail

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

BioTech 365

Glaukos Announces Participation in J.P. Morgan Healthcare Conference Glaukos Announces Participation in J.P. Morgan Healthcare Conference SAN CLEMENTE, Calif.

75
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Ridgeback Biotherapeutics’ Ebola treatment scores FDA approval

Pharma Times

Ebanga approved to treat Ebola in adult and paediatric patients

article thumbnail

Google’s Verily eyes 2021 growth after £700m funding round

pharmaphorum

Verily is planning “significant and focused growth” in 2021 after closing a $700 million funding round from investors including its parent company, and Google holding firm, Alphabet. The capital injection will support wide-ranging plans for the new year that include several life sciences programmes in surgery, pathology and immunology, which would add to the digital ophthalmology joint venture it signed with Japan’s Santen in February.

article thumbnail

Vicore Pharma’s C21 med shows promise in COVID-19 study

Pharma Times

Drug is being studied in hospitalised COVID-19 patients

Drugs 119
article thumbnail

Coronavirus Vaccine Distribution Could Get Chaotic

NY Times

There are already signs that the rollout will be messy, confusing and chaotic.

article thumbnail

The New Clinical Trial Supply Chain: Resilient, Flexible, and Patient-Centric

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.

article thumbnail

Algernon Pharmaceuticals Announces Last Patient Out in Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

The Pharma Data

VANCOUVER, British Columbia, Dec. 24, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that the last patient from the Phase 2b part of its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, has now completed treatment as well as the required two-week follow up.

article thumbnail

Atomic-scale nanowires can now be produced at scale

Scienmag

Scalable synthesis of transition metal chalcogenide nanowires for next-gen electronics Credit: Copyright 2020 American Chemical Society (ACS) Tokyo, Japan – Researchers from Tokyo Metropolitan University have discovered a way to make self-assembled nanowires of transition metal chalcogenides at scale using chemical vapor deposition. By changing the substrate where the wires form, they can tune how […].

article thumbnail

AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers’Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects

The Pharma Data

OCALA, Fla., Dec. 24, 2020 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) announced today that the post-COVID-19 “Long Hauler” portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval from the Institutional Review Board (IRB) for a public notification of potential patient enrollment. Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen.

article thumbnail

New patent for Vanda Pharms drug HETLIOZ

Drug Patent Watch

Annual Drug Patent Expirations for HETLIOZ Hetlioz is a drug marketed by Vanda Pharms Inc and is included in one NDA. It is available from one supplier. There are thirteen…. The post New patent for Vanda Pharms drug HETLIOZ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.